Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2021

Q2 2021 biggest moves
  • OMICOMIC

    SINGULAR GENOMICS SYSTEMS IN

    New listing

    4.4% of portfolio

  • AHCOAHCO

    AdaptHealth

    3.2× the shares

    now 3.6% of portfolio

  • BSXBSX

    Boston Scientific

    Sold out

    was 2.3% of portfolio

  • ALXNALXN

    ALEXION PHARMACEUTICALS

    Sold out

    was 1.9% of portfolio

106 changes in all

Top Holdings143 positions

Checking export access…
Activity:
VTRS

Viatris Inc.

18.8M$269M4.8%$14.37-20.00%
3 qtrssince 2020-Q4
Increased
62
OMIC
OMICDelisted

SINGULAR GENOMICS SYSTEMS IN

9.1M$250.4M4.4%——
1 qtr
New
85
??
INVITAE CORPDelisted
Bond
163.4M$221.7M3.9%——
4 qtrssince 2020-Q3
Unchanged
0
??
CAREMAX INCDelisted
16.8M$216.4M3.8%——
1 qtr
New
85
AHCO

AdaptHealth Corp.

7.4M$201.6M3.6%$24.79+10.56%
7 qtrssince 2019-Q4
Increased
90
157.4M$156.6M2.8%——
4 qtrssince 2020-Q3
Increased
55
??
GLAUKOS CORPDelisted
Bond
90M$153.5M2.7%——
1 qtr
New
78
??
NATERA INCDelisted
Bond
45M$136.3M2.4%——
1 qtr
New
78
80M$131.2M2.3%——
2 qtrssince 2021-Q1
Unchanged
0
ORGO

Organogenesis Holdings Inc.

7.2M$120M2.1%$17.28-3.84%
2 qtrssince 2021-Q1
Increased
83
52.5M$112M2.0%——
1 qtr
New
69
??
NUVASIVE INCDelisted
Bond
97M$101.3M1.8%——
1 qtr
New
68
EWTX

Edgewise Therapeutics, Inc.

3.9M$83.9M1.5%$32.50-34.37%
2 qtrssince 2021-Q1
Unchanged
0
LUNG

Pulmonx Corporation

1.8M$79.5M1.4%$50.95-13.41%
3 qtrssince 2020-Q4
Increased
74
??
INSULET CORPDelisted
Bond
57.6M$78.2M1.4%——
3 qtrssince 2020-Q4
Unchanged
0
41.8M$77.8M1.4%——
4 qtrssince 2020-Q3
Increased
74
AFIB
AFIBDelisted

ACUTUS MED INC

4.3M$73.7M1.3%——
4 qtrssince 2020-Q3
Unchanged
0
CNC

Centene Corporation

995,000$72.6M1.3%$60.25+21.05%
7 qtrssince 2019-Q4
Decreased
0
NBIX

Neurocrine Biosciences, Inc.

725,000$70.6M1.3%$97.25+0.07%
2 qtrssince 2021-Q1
Unchanged
0
PCRX

Pacira BioSciences, Inc.

1.1M$69.6M1.2%$37.51+61.76%
6 qtrssince 2020-Q1
Decreased
0
$5.6B
AUM
143
Positions
Q2 2021
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q1$3,151,113,0000.539146165786%
2020-Q2$3,433,887,0008.97378164477%
2020-Q3$4,106,901,00019.5991889075%
2020-Q4$5,059,782,00023.2019471616%
2021-Q1$4,758,345,000-5.95750963184%
2021-Q2$5,629,668,00018.3114717407%
Activity profile
$ moved · Q2'21
New49%Increased18%Decreased7%Exited26%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.5 quarters
<1Q24%1-4Q45%1-2Y31%2Y+0%

Deerfield Management Company, L.P. manages $5.6B across 143 positions as of Q2 2021. Top holdings: VTRS (4.8%), OMIC (4.4%), INVITAE CORP (3.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$6B
VTRS4.78%
OMIC4.45%
INVITAE CORP3.94%
CAREMAX INC3.84%
AHCO3.58%
AERIE PHARMA2.78%
GLAUKOS CORP2.73%
NATERA INC2.42%
Bridgebio Ph2.33%
ORGO2.13%
Other1.99%

Portfolio allocation by GICS sector

Sectors2
Healthcare69.22%
Unknown30.78%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used